KODIAK SCIENCES INC. Operating Lease, Right-of-Use Asset, Amortization Expense
KODIAK SCIENCES INC. (KOD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $4.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.08M, a 6.79% increase year-over-year.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.23M, a 4.99% increase year-over-year.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $1.97M, a 4.13% decline year-over-year.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $1.95M, a 2.98% decline year-over-year.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $7.99M, a 0.05% decline from fiscal 2024.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $8.00M, a 4.54% increase from fiscal 2023.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $7.65M, a 6.16% increase from fiscal 2022.
- KODIAK SCIENCES INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $7.21M, a 6.53% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.31M 10-Q · filed 2026-08-13 | $6.28M derived: sum of 3 quarters · filed 2026-08-13 | $8.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.23M 10-Q · filed 2026-05-07 | $4.20M derived: sum of 2 quarters · filed 2026-05-07 | $6.15M derived: sum of 3 quarters · filed 2026-05-07 | $8.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.92M derived: sum of 2 quarters · filed 2026-03-31 | $5.87M derived: sum of 3 quarters · filed 2026-08-13 | $7.99M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.90M derived: sum of 2 quarters · filed 2026-08-13 | $6.02M 10-Q · filed 2025-11-13 | $8.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.07M 10-Q · filed 2026-08-13 | $6.13M derived: sum of 3 quarters · filed 2026-08-13 | $8.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.13M 10-Q · filed 2026-05-07 | $4.18M derived: sum of 2 quarters · filed 2026-05-07 | $6.19M derived: sum of 3 quarters · filed 2026-05-07 | $8.18M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $4.07M derived: sum of 2 quarters · filed 2026-03-31 | $6.05M derived: sum of 3 quarters · filed 2026-03-31 | $8.00M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.00M derived: sum of 2 quarters · filed 2025-11-13 | $5.94M 10-Q · filed 2025-11-13 | $7.88M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.93M 10-Q · filed 2025-08-13 | $5.87M derived: sum of 3 quarters · filed 2026-03-31 | $7.83M derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-03-31 | $1.94M 10-Q · filed 2025-05-14 | $3.88M derived: sum of 2 quarters · filed 2026-03-31 | $5.85M derived: sum of 3 quarters · filed 2026-03-31 | $7.75M derived: sum of 4 quarters · filed 2026-03-31 |
| 2023-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $3.90M derived: sum of 2 quarters · filed 2026-03-31 | $5.80M derived: sum of 3 quarters · filed 2026-03-31 | $7.65M 10-K · filed 2026-03-31 |
| 2023-09-30 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $3.87M derived: sum of 2 quarters · filed 2024-11-14 | $5.71M 10-Q · filed 2024-11-14 | $7.46M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $3.75M 10-Q · filed 2024-08-14 | $5.49M derived: sum of 3 quarters · filed 2025-03-27 | $7.21M derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-03-31 | $1.85M 10-Q · filed 2024-05-15 | $3.59M derived: sum of 2 quarters · filed 2025-03-27 | $5.31M derived: sum of 3 quarters · filed 2025-03-27 | $7.15M derived: sum of 4 quarters · filed 2025-03-27 |
| 2022-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $3.46M derived: sum of 2 quarters · filed 2025-03-27 | $5.30M derived: sum of 3 quarters · filed 2025-03-27 | $7.21M 10-K · filed 2025-03-27 |
| 2022-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.55M derived: sum of 2 quarters · filed 2023-11-14 | $5.46M 10-Q · filed 2023-11-14 | $7.36M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.74M 10-Q · filed 2023-08-14 | $5.64M derived: sum of 3 quarters · filed 2024-03-28 | $7.55M derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-03-31 | $1.90M 10-Q · filed 2023-05-15 | $3.80M derived: sum of 2 quarters · filed 2024-03-28 | $5.71M derived: sum of 3 quarters · filed 2024-03-28 | |
| 2021-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.81M derived: sum of 2 quarters · filed 2024-03-28 | $7.71M 10-K · filed 2024-03-28 | |
| 2021-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $5.81M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $3.90M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $3.73M 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |